264 related articles for article (PubMed ID: 27406316)
21. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.
Chen H; Singh RR; Lu X; Huo L; Yao H; Aldape K; Abraham R; Virani S; Mehrotra M; Mishra BM; Bousamra A; Albarracin C; Wu Y; Roy-Chowdhuri S; Kanagal-Shamanna R; Routbort MJ; Medeiros LJ; Patel KP; Broaddus R; Sahin A; Luthra R
Oncotarget; 2017 Feb; 8(7):10845-10857. PubMed ID: 28125801
[TBL] [Abstract][Full Text] [Related]
22. Validation of HER2 Status in Whole Genome Sequencing Data of Breast Cancers with the Ploidy-Corrected Copy Number Approach.
Wojtaszewska M; Stępień R; Woźna A; Piernik M; Sztromwasser P; Dąbrowski M; Gniot M; Szymański S; Socha M; Kasprzak P; Matkowski R; Zawadzki P
Mol Diagn Ther; 2022 Jan; 26(1):105-116. PubMed ID: 34932189
[TBL] [Abstract][Full Text] [Related]
23. Establishment of two basal-like breast cancer cell lines with extremely low tumorigenicity from Taiwanese premenopausal women.
Kuo WL; Ueng SH; Wu CH; Lee LY; Lee YS; Yu MC; Chen SC; Yu CC; Tsai CN
Hum Cell; 2018 Apr; 31(2):154-166. PubMed ID: 29484537
[TBL] [Abstract][Full Text] [Related]
24. Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.
Verschoor N; Smid M; Jager A; Sleijfer S; Wilting SM; Martens JWM
Breast Cancer Res; 2023 Nov; 25(1):145. PubMed ID: 37968696
[TBL] [Abstract][Full Text] [Related]
25. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
26. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
[TBL] [Abstract][Full Text] [Related]
27. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
28. Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2
Vasmatzis G; Wang X; Smadbeck JB; Murphy SJ; Geiersbach KB; Johnson SH; Gaitatzes AG; Asmann YW; Kosari F; Borad MJ; Serie DJ; McLaughlin SA; Kachergus JM; Necela BM; Thompson EA
BMC Cancer; 2018 Jul; 18(1):738. PubMed ID: 30005627
[TBL] [Abstract][Full Text] [Related]
29. A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications.
Marotta M; Chen X; Inoshita A; Stephens R; Budd GT; Crowe JP; Lyons J; Kondratova A; Tubbs R; Tanaka H
Breast Cancer Res; 2012 Nov; 14(6):R150. PubMed ID: 23181561
[TBL] [Abstract][Full Text] [Related]
30. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
32. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
[TBL] [Abstract][Full Text] [Related]
33. Molecular characterisation of cell line models for triple-negative breast cancers.
Grigoriadis A; Mackay A; Noel E; Wu PJ; Natrajan R; Frankum J; Reis-Filho JS; Tutt A
BMC Genomics; 2012 Nov; 13():619. PubMed ID: 23151021
[TBL] [Abstract][Full Text] [Related]
34. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.
Prat A; Carey LA; Adamo B; Vidal M; Tabernero J; Cortés J; Parker JS; Perou CM; Baselga J
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139534
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.
Rao PS; Labhart M; Mayhew SL; Thirumala S; Rao US
Tumour Biol; 2014 Jul; 35(7):7267-73. PubMed ID: 24777335
[TBL] [Abstract][Full Text] [Related]
36. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
37. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
[TBL] [Abstract][Full Text] [Related]
38. The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors.
Tina E; Lindqvist BM; Gabrielson M; Lubovac Z; Wegman P; Wingren S
BMC Cancer; 2012 Aug; 12():350. PubMed ID: 22883974
[TBL] [Abstract][Full Text] [Related]
39. PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.
Cizkova M; Susini A; Vacher S; Cizeron-Clairac G; Andrieu C; Driouch K; Fourme E; Lidereau R; Bièche I
Breast Cancer Res; 2012 Feb; 14(1):R28. PubMed ID: 22330809
[TBL] [Abstract][Full Text] [Related]
40. Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.
Xu H; Yan M; Patra J; Natrajan R; Yan Y; Swagemakers S; Tomaszewski JM; Verschoor S; Millar EK; van der Spek P; Reis-Filho JS; Ramsay RG; O'Toole SA; McNeil CM; Sutherland RL; McKay MJ; Fox SB
Breast Cancer Res; 2011 Jan; 13(1):R9. PubMed ID: 21255398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
